PsychedelicNewsBreaks

ThursdayJun 23, 2022 2:16 pm

PsychedelicNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) to Present at 1st Annual H.C. Wainwright Mental Health Conference

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, today confirmed details regarding Delic Corp CEO Matt Stang’s virtual attendance at the first annual H.C. Wainwright Mental Health Conference on June 27, 2022. The inaugural event will be held at the Lotte New York Palace Hotel and feature a full day of company presentations, networking opportunities and one-on-one investor meetings with a focus on neuropsychiatry, psychedelics and more. During this year’s conference, Stang will present the company’s strategic outlook for the remainder of the year and how the company is…

Continue Reading

WednesdayJun 22, 2022 2:50 pm

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Business Highlights, FY 2022 Results

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today reported recent business highlights and audited financial results for its fiscal year ended March 31, 2022. In addition, the company reiterated its anticipated pipeline and strategic milestones for the remainder of 2022. “Cybin made important progress across the board in recent months, accelerating both our pipeline of proprietary investigational psychedelic-based treatments and strategic partnership programs. Our successful preclinical work has set the foundation for a seamless transition to in-human trials,” said Cybin CEO Doug Drysdale. “Over a very short time horizon, we have evolved…

Continue Reading

ThursdayJun 16, 2022 4:34 pm

PsychedelicNewsBreaks – Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Delic Labs to Present at Grow Up Conference and Expo

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, today shared details regarding Dr. Markus Roggen, president and CSO of Delic Labs, and his participation in the upcoming Grow Up Conference and Expo. During the event taking place on June 20-22, 2022, in Victoria, British Columbia, Dr. Roggen will participate in multiple panels and share details on the advancement of psychedelics as well as improvements of cannabis extraction technology. Interested parties should visit https://ibn.fm/UXl5c to learn more about the Grow Up Conference and Expo and purchase tickets for the engaging…

Continue Reading

ThursdayJun 16, 2022 2:59 pm

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Present at H.C. Wainwright 1st Annual Mental Health Conference

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that its CEO Doug Drysdale will participate in a fireside chat and panel discussion at the H.C. Wainwright 1st Annual Mental Health Conference. The event is slated to take place at the Lotte New York Palace Hotel on June 27, 2022. Drysdale’s fireside chat will be webcast live at 10:30 a.m. ET on the day of the conference. In addition, Drysdale will participate in a panel discussion titled “Navigating Depression: Current Understanding and Future Treatments” at 12:45 p.m. ET. Interested parties should visit…

Continue Reading

WednesdayJun 15, 2022 3:10 pm

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Collaborating to Progress Mission to Create Safe, Effective Therapeutics

Cybin (NYSE American: CYBN) (NEO: CYBN), a clinical-stage biopharmaceutical company committed to progressing Psychedelics to Therapeutics(TM), has joined the ranks of companies dedicated to finding and offering effective solutions to those suffering from mental health conditions. “The company announced that pilot results from its sponsored feasibility study evaluating Flow, Kernel’s quantitative neuroimaging technology, indicate that ketamine-induced changes in the brain’s functional connectivity persisted for several days after receiving the substance,” a recent article reads. “The purpose of the four-week study is to evaluate the altered state of consciousness of an individual following the administration of ketamine. The Kernel Flow headset…

Continue Reading

WednesdayJun 15, 2022 2:51 pm

PsychedelicNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Committed to Building on Its Holistic Approach to Mental Health Wellness

Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, is devoted to finding solutions for mental ailments — not simply by easing symptoms, but by attacking the root causes of the difficulties, utilizing a toolbox of innovative, therapeutic substances. “Recently, Delic announced that six of its clinic locations will launch a specialized therapy that has the potential to boost natural energy stores and immunity, brain and DNA function, and cell communication. The NAD+ (nicotinamide adenine dinucleotide) infusion therapy is administered intravenously or intramuscularly and has previously shown evidence that such treatments support the creation of new cells, neuropathways…

Continue Reading

MondayJun 13, 2022 1:16 pm

PsychedelicNewsBreaks – Silo Pharma Inc. (SILO) Committed to Psilocybin, Anti-Inflammatory Research

Silo Pharma (OTCQB: SILO) still believes in medicinal mushrooms despite the fact that they are currently outlawed by the U.S. government (though legal in Oregon and decriminalized in various cities and states). Recently, the company announced that the Translational Psychedelic Research (“TrPR”) Program at the University of California San Francisco (“UCSF”) had successfully dosed [with psilocybin] patients who have Parkinson’s disease. “Silo is exploring psilocybin’s anti-inflammatory possibilities in patients exhibiting signs of Parkinson’s,” reads a recent article. “Silo’s commitment to psilocybin and anti-inflammatory research includes: executing an option agreement with the University of Maryland, Baltimore, studying novel system-homing peptides that…

Continue Reading

FridayJun 10, 2022 3:16 pm

PsychedelicNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Leveraging Profitable Model to Scale Best-in-Class Care Directly to Patients

Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, owns and operates an assortment of related businesses and is backed by a team of industry and cannabis veterans. The company’s mission is to provide education, research, high-quality products, and effective treatment options to the masses. “In a January interview, Delic CEO and Co-Founder Matt Stang explained that there are 51.5 million Americans who have experienced a mental health condition, and the ongoing pandemic has only exacerbated the crisis. This increase in mental health issues has led to a stronger demand for alternatives to current treatments with lasting outcomes…

Continue Reading

FridayJun 10, 2022 10:49 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Awarded Board Approval for CYB003 Phase 1/2a Clinical Trial

Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, received Institutional Review Board (“IRB”) approval to begin its planned phase 1/2a clinical trial. The trial, the first-in-human phase 1/2a trial evaluating CYBN’s proprietary deuterated psilocybin analog CYB003, is slated to begin in mid-2022.The study will evaluate CYB003 for the treatment of major depressive disorder (“MDD”).  Cybin applied for IRB approval just last month. According to the announcement, Cybin wholly owned subsidiary Cybin IRL Limited has partnered with Clinilabs Drug Development Corporation to conduct the randomized, double-blind, placebo-controlled study. The study involves participants receiving two administrations of…

Continue Reading

TuesdayJun 07, 2022 11:03 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Acquisition of Entheon Biomedical’s DMT Clinical Study

Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has entered an agreement to acquire the largest phase 1 DMT study conducted to date. The acquisition, conducted through Cybin IRL Limited, a wholly owned subsidiary of Cybin, is expected to accelerate Cybin’s CYB004 program timeline by an estimated nine months; CYB004 is Cybin’s proprietary deuterated DMT molecule designed for the potential treatment of anxiety disorders.. The phase 1 N,N-dimethyltryptamine (“DMT”) study is focused on evaluating pharmacokinetics/pharmacodynamics of DMT currently underway and is expected to significantly impact the clinical path forward. Renamed CYB004-E, the phase 1 EBRX-101…

Continue Reading